20 June 2013
Keywords: b-ms, gains, rights, eisai, antifungal, japan, licensed
Article | 23 December 1996
Eisai of Japan has licensed its oral broad-spectrum antifungal triazole,
ER-30346, to US company Bristol-Myers Squibb, which gets exclusive
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 December 1996
19 June 2013
© 2013 thepharmaletter.com